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Abstract: 
A variety of epidemiological trials have suggested that higher intake of lycopene-containing 
foods (primarily tomato products) or blood lycopene concentrations are associated with 
decreased cardiovascular disease and prostate cancer risk. Of the carotenoids tested, lycopene 
has been demonstrated to be the most potent in vitro antioxidant leading many researchers to 
conclude that the antioxidant properties of lycopene are responsible for disease prevention. In 
our review of human and animal trials with lycopene, lycopene-containing extracts, or tomato 
products, there is limited support for the in vivo antioxidant function for lycopene. Moreover, 
tissue levels of lycopene appear to be too low to play a meaningful antioxidant role. We 
conclude that there is an overall shortage of supportive evidence for the “antioxidant hypothesis” 
as lycopene’s major in vivo mechanism of action. Our laboratory has postulated that metabolic 
products of lycopene, the lycopenoids, may be responsible for some of lycopene’s reported 
bioactivity. 
 
Keywords:  lycopene; lycopenoids; carotenoids; tomato; antioxidant; prostate cancer; 
cardiovascular disease; oxidative stress; vitamin E; mechanism 
 
 
 
 
 
2 
 
Introduction 
 
Maintaining the balance of oxidants and antioxidants within the intracellular and 
extracellular environment is essential for optimal metabolism and health. We derive energy from 
oxidative metabolism of dietary macronutrients, but in doing so produce reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) that can damage lipids, proteins, and DNA. Under 
normal conditions, we have mechanisms to counteract excess ROS or RNS thereby protecting us 
from an imbalance of excess oxidants often referred to as “oxidative stress”. Sies [1, 2] reminds 
us that we have an antioxidant enzyme network that constitutes our major defense against 
oxidative stress. These enzymes intercept ROS and RNS, repair damage to macromolecules, 
such as DNA, and adapt to changing levels of short and long-term oxidative stress. 
Small molecules such as carotenoids, vitamins, and some minerals contribute to 
antioxidant defense as part of enzymes (e.g. selenium in glutathione peroxidases, manganese in 
superoxide dismutase), or play a more direct role by intercepting and/or quenching ROS or RNS 
(e.g. vitamins E and C). Carotenoids can function as chain-breaking antioxidants. The quenching 
of singlet oxygen or peroxyl radicals by carotenoids directly transfers energy between these 
molecules [3]. That energy can be dissipated to the aqueous environment as heat or destroy the 
carotenoid molecule itself. To be effective antioxidants, carotenoids must be present in sufficient 
concentrations and at the specific location where the ROS or RNS are generated [1]. 
Researchers have postulated that many chronic diseases; cardiovascular disease, cancer, 
diabetes, eye diseases and aging itself are the result of long-term oxidative stress. The focus of 
this review is whether lycopene is in sufficient amounts and right location(s) to be a meaningful 
antioxidant in vivo. Additionally, we review lycopene’s proposed mechanisms of action and 
suggest that lycopene metabolites, termed lycopenoids [4], may be important bioactive 
molecules that contribute to the decrease in chronic disease risk seen with the consumption of 
high lycopene-containing foods. 
 
High carotenoid-containing foods and decreased disease risk 
 
There is almost universal agreement that consumption of carotenoid-containing fruits and 
vegetables is associated with decreased incidence of chronic diseases such as heart disease and 
cancer. It was assumed that carotenoids in these foods are responsible, or at least contribute to 
these epidemiological findings, but this assumption requires validation with intervention trials. 
However, clinical trials with single small molecules like vitamin E, vitamin C, or β-carotene 
largely have been disappointing [5]. As described earlier, antioxidant defense is multifaceted, 
thus supplementation with an individual small molecule, unless deficient, likely will have little 
effect on chronic disease incidence. On the other hand, a portfolio of small molecules, such as 
those found in fruits and vegetables, may provide significant protection. 
 
Relationship of lycopene-containing foods and cardiovascular disease  
 
A variety of epidemiological studies have suggested that intake of lycopene-containing 
foods, as well as blood lycopene concentrations, are inversely related to incidence of 
cardiovascular disease and prostate cancer [6-8]. One notable epidemiological study examined 
carotenoid and tocopherol adipose concentrations in myocardial infarction patients compared to 
age-matched controls [9]. Adipose concentrations of these fat-soluble antioxidants are believed 
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to reflect long-term intake of these compounds. Higher adipose lycopene concentrations were 
independently associated with decreased risk of myocardial infarction (OR = 0.52, 10th vs. 90th 
percentile). While not all epidemiological studies agree, most support an inverse association 
between lycopene intake or tissue concentrations and cardiovascular disease [7]. 
 
Epidemiological relationship of lycopene/tomato intake and prostate cancer 
 
A 2004 meta-analysis examined the relationship between lycopene/tomato intake and the 
risk of prostate cancer [10]. The authors found that serum lycopene [RR = 0.71 (0.59-0.92), 7 
studies], lycopene intake [RR = 0.89 (0.81-0.98, 10 studies)], and cooked tomato intake [RR = 
0.81 (0.71-0.92), 6 studies], but not raw tomato intake [RR = 0.89 (0.80-1.00), 9 studies] were 
associated with a significant decrease in prostate cancer risk. A number of studies were not 
included in the analysis [11-15], or were published after the meta-analysis [16-29]. Some of 
these studies report evidence for decreased prostate cancer risk with increased lycopene/tomato 
exposure [11, 12, 14-16, 20, 21, 27, 29], while some show little to no effect [13, 17, 18, 22, 23, 
25, 26, 28]. 
 
Lycopene/tomato and prostate cancer clinical trials 
 
There have been 12 small clinical trials investigating the potential impact of lycopene or 
tomato consumption on prostate cancer risk/progression. These have mostly been in patients; 
with prostate cancer scheduled for a prostatectomy, with benign prostatic hyperplasia, or at high-
risk of developing prostate cancer. Almost all of these have reported prostate specific antigen 
(PSA) response (decreased concentration, decreased velocity, increased stabilization) as an 
outcome related to disease progression or prostate health. Overall, the majority of these trials 
have found evidence of improved PSA response [30-40] with lycopene or tomato consumption, 
whereas a few have not [41-43]. It is important that these trials be viewed in the context of their 
small size and general lack of an appropriate control group. 
 
Lycopene/tomato intake and prostate cancer in animal studies 
 
In our laboratory, a 10% tomato powder diet, but not lycopene alone (250 mg/kg diet), 
significantly decreased NMU-induced prostate cancer incidence in F344 rats [44]. In the 
Dunning R3327-H prostate transplantable rat tumor model, we found that 10% tomato powder 
was more effective in decreasing tumor growth than lycopene alone [45]. In a similar, but faster 
growing tumor model, lycopene alone (200 mg/kg diet) had no effect on Dunning MatLyLu 
tumor growth or necrosis levels [46]. One publication [47] evaluated two chemical prostate 
cancer models with varying results for lycopene in F344 rats. First, 15 mg lycopene per kg of 
diet decreased prostatic interepithelial neoplasia incidence when administered after the 
carcinogen, 7,12-dimethylbenz[a]anthracene (DMBA).  However, lycopene (5, 15, or 45 mg/kg 
diet) did not alter 2-amino-1-methylimidazol[4,5-b]pyridine (PhIP) induced prostate cancer 
incidence [47]. In a nude mouse model, 100 and 300 mg/kg body weight, but not 10 mg/kg body 
weight of gavaged lycopene, significantly inhibited human androgen-independent DU-145  
prostate cancer xenograph growth [48]. In another nude mouse model, orally gavaged lycopene 
(5 or 50mg/kg body weight) failed to decrease androgen-independent human PC-346C prostate 
cancer xenograph growth, but the combination of low dose lycopene plus vitamin E significantly 
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decreased tumor growth [49]. Together these studies suggest lycopene moderately alters prostate 
cancer development and/or tumor growth in experimental animals. Moreover, it appears that 
lycopene is one of several bioactive compounds in tomatoes that may contribute to decreasing 
the development and/or progression of prostate cancer. 
 
Is lycopene bioactive in health promotion? 
 
Dietary intake of lycopene, or blood or tissue lycopene, may simply serve as a marker of 
tomato intake. Lycopene may provide some of the cardiovascular or cancer protection associated 
with tomato intake, but likely is not the only bioactive compound in tomatoes. Tomatoes contain 
significant quantities of vitamins C and E, folate, polyphenols, and other carotenoids such as 
phytoene and phytofluene [6]. Significant concentrations of lycopene are only found in a select 
number of foods (tomato, watermelon, guava, pink grapefruit), with about 85% of lycopene 
intake in the U.S. coming from fresh and processed tomato products [50]. Thus, future work 
should focus not only on lycopene but also upon other tomato components, with consideration 
given to potential additive or synergistic interactions between bioactives. 
 
In vitro and ex vivo antioxidant effects of lycopene 
 
There are a number of ex vivo studies that demonstrate delayed chemically-induced LDL 
oxidation lag time from blood obtained from human subjects fed tomato products or tomato 
extracts [7]. However, supplementation of lycopene alone rarely significantly decreases serum 
lipid peroxidation or ex vivo LDL oxidation, thus interactions with other tomato compounds may 
be occurring [7]. For example, the combination of lycopene and the tomato polyphenol, rutin, 
synergistically decreased copper-induced LDL oxidation lag time [51]. 
In 2000, the panel on Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium and 
Carotenoids evaluated the potential health impact of β-carotene and other carotenoids [52]. After 
extensively evaluating the literature, they concluded that there was evidence that β-carotene was 
an antioxidant in vitro, but that there was not convincing evidence that substantially increasing β-
carotene intake above current levels had a significant effect on antioxidant status measures. 
Lycopene was not specifically addressed. However, the authors of this review have found no 
compelling evidence since the publication of that panel’s report to suggest that elevation of β-
carotene or lycopene significantly improves antioxidant status measures. 
 
Lycopene as an in vivo antioxidant: the evidence 
 
To identify the evidence to support lycopene as an in vivo antioxidant we utilized pubmed 
and the search terms “lycopene AND antioxidant” and a previous review to identify publications 
on this topic [53]. Many studies utilized lycopene extracts (mostly from tomatoes), which may 
contain other compounds, thus these studies were separated from those that reported using a pure 
lycopene source. In addition, we separated human studies from animal studies resulting in four 
groups of studies: human lycopene studies (Table 1, n =3), human lycopene extract studies 
(Table 2, n = 9), animal lycopene studies (Supplemental Table 1, n = 11), and animal lycopene 
extract studies (Supplemental Table 2, n = 18). 
All three human lycopene studies identified were double-blind, placebo-controlled trials 
(Table 1). Devaraj et al. examined the antioxidant potential of 8 weeks of lycopene 
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supplementation (6.5, 15, 30 mg/d) following a 2 week washout period in healthy men and 
women 40 years or older. None of the lycopene doses had an effect on LDL oxidation rate, 
plasma lipid peroxidation markers (malondialdehyde [MDA] and 4-hydroxynonenal [HNE]), and 
urinary F2-isoprostanes. However, the 30 mg/d dose did decrease lymphocyte DNA damage and 
urinary 8-OHdG concentrations compared to baseline [54]. A similarly designed study was 
undertaken in diabetics supplemented with 10 mg/d of lycopene. Supplementation did not alter 
total antioxidant capacity or oxidized-LDL antibody levels, but did decrease serum MDA levels 
compared to baseline [55]. Zhao et al. also used a 2 week washout followed by 56 days of 
supplementation of 12 mg/d of lycopene to healthy, nonsmoking, postmenopausal women. 
Lycopene supplementation decreased lymphocyte DNA damage, but did not prevent hydrogen 
peroxide-induced DNA damage [56]. 
Of the nine human lycopene extract studies (Table 2), only four provide some evidence to 
suggest that lycopene is an in vivo antioxidant and in each case other measured antioxidant 
markers were not altered. The animal data (Supplemental Tables 1 & 2) are more difficult to 
interpret because of model, species, and lycopene administration differences, but overall are 
more supportive of lycopene having antioxidant action than the human studies. Nevertheless, 
when considering the data as a whole, there is an overall shortage of supportive evidence, such 
that we conclude that it is not convincing that lycopene is an in vivo antioxidant. More well 
designed studies, especially in humans, are needed to further clarify this potential mechanism. 
 
Are lycopene concentrations high enough in body tissues? 
 
There is almost universal agreement that lycopene is an excellent in vitro antioxidant, 
especially in quenching singlet oxygen, and may be the best dietary molecule in this regard [57]. 
It is projected that intact lycopene with its 11 conjugated double bonds will also quench peroxyl 
radicals in LDL particles or cellular membranes [3]. Carotenoids, while highly concentrated in 
many foods, are not well absorbed and rarely accumulate in high concentrations in blood and 
tissues [58]. Lycopene is generally the carotenoid in highest concentration in American’s serum, 
nevertheless, the average adult U.S. serum concentrations are less than 0.013 µm/dL according to 
NHANES III data [52]. In our experience, it is difficult to exceed 0.14µm/dL lycopene in serum, 
even when providing a lycopene-enriched diet for a week or more to healthy subjects. These 
levels fall far short of serum α-tocopherol concentrations [59]. 
When pooling samples from 10 healthy subjects, Milde et.al. found 11.6 molecules of α-
tocopherol per LDL molecule but only 0.9, 0.9 and 0.5 molecules of  lycopene, lutein, and β-
carotene, respectively [51]. A separate study found 0.7 molecules of lycopene per LDL molecule 
from pooled serum of seven normolipodemic subjects [60]. It seems unlikely that 1 molecule of 
lycopene in a LDL particle would have much impact on LDL oxidation. Moreover, when Milde 
and coworkers enriched human LDL 2-fold with lycopene, it did not increase LDL resistance to 
copper-induced oxidation.  
We and others have measured carotenoid concentrations in human tissues, and lycopene 
is generally the highest carotenoid in individual tissues [61, 62]. We also evaluated human 
prostate and determined that lycopene was the predominant carotenoid, but is generally lower in 
concentration than other tissues [63]. Freeman and co-workers [64] found that α-tocopherol 
concentrations were 162-fold higher than lycopene in the human prostate. In LDL, the molar α-
tocopherol concentration is 17-fold higher than lycopene [60]. In nonsmokers, Peng et al. found 
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plasma and skin α-tocopherol concentrations to be 53-fold and 269-fold higher, respectively, 
than lycopene concentrations [59]. 
Lycopene was shown to be 2 and 10-fold more efficient at quenching singlet oxygen than 
β-carotene and α-tocopherol, respectively, in vitro [57]. But given the substantially higher α-
tocopherol content in serum, LDL, and human tissues, even if α-tocopherol has a 10-fold lower 
antioxidant potential [57], it seems unlikely that lycopene plays a meaningful a role as a fellow 
fat-soluble antioxidant. That is not to say that lycopene, or its metabolites, may not have 
biological effects, as will be discussed below. 
 
Potential in vivo mechanisms of action of lycopene 
 
While there has been great interest in the antioxidant properties of lycopene, other 
mechanisms of action that may or may not be related to antioxidant function, have also received 
research attention and have been reviewed previously [65-67]. The following is an abbreviated 
overview focused on the in vivo evidence to support lycopene’s mode of action beyond its 
potential antioxidant function (see Table 3). 
Apoptosis is controlled through many tightly-regulated steps which may be modified by 
dietary intervention. One human [31, 68] and six animal [45, 48, 69-72] studies suggest that 
lycopene induces apoptosis of cancer cells, whereas one human study [32] found no effect. In 
contrast, in a mouse emphysema model lycopene decreased the apoptosis rate [73]. The little in 
vivo evidence available suggests that lycopene induces apoptosis in cancer cells. 
Decreases in cell growth can also be achieved through cell cycle inhibition. We found 2 
animal studies that suggest lycopene inhibits cell cycle progression in an oral cancer model and a 
subcutaneous prostate cancer mouse model [48, 74]. Overall, more in vivo studies are necessary 
to determine whether lycopene alters cell cycle progression. 
Several studies have suggested an inverse correlation between the insulin-like growth 
factor-1 (IGF-1) axis and prostate cancer incidence [75, 76]. We identified 12 human or animal 
studies investigating the relationship between IGF-1, its receptor protein (IGF-1R), its binding 
proteins (IGFBP-1 or IGFBP-3), and lycopene or tomato product supplementation. Only two 
human studies (colon cancer patients or healthy subjects) report a positive impact of lycopene in 
decreasing IGF-1, IGF-1R, or increasing IGFBP-1 or IGFBP-3 [77, 78]. Three animal studies 
suggest that lycopene decreases IGF-1 or increases IGFBP-1 or IGFBP-3 [46, 71, 79]. In 
contrast, five studies found no relationship between lycopene intake and IGF-1 level [32, 39, 40, 
80, 81]. Lastly, one trial investigated the effects of lycopene on the IGF-1 axis in two female 
populations [82]. Only when the two populations were separated were significant effects 
identified. There was a decrease in IGF-1 in women at high familial breast cancer risk, but no 
effect on IGF-1 and IGFBP-3 levels with lycopene consumption in premenopausal breast cancer 
survivors [82]. Thus, the existing in vivo data is mixed in regards to the impact of lycopene on 
the IGF-1 axis. 
Gap junction communication allows small molecular signaling between cells through 
channels that are formed by gap junction proteins such as connexin 43. Only one in vivo study 
found a positive association between gap junction communication or connexin 43 expression 
with lycopene consumption [83].  Krutovskikh, et al. investigated the effect of gavaged lycopene 
on gap junction communication in rat liver. Interestingly, the lower dose (5mg/kg/d) enhanced 
communication while the higher dose (50mg/kg/d) inhibited communication. A randomized 
clinical trial of lycopene supplementation reported a near significant increase in connexin 43 
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protein levels [32]. Overall, there is relatively little in vivo evidence to support an increase in gap 
junction communication with lycopene consumption. 
The risk of prostate cancer is strongly associated with androgen status [84, 85] and 
lycopene may modulate androgen metabolism. Serum testosterone concentrations were 
significantly decreased in rats fed lycopene for 4 days [86], while feeding lycopene for 22 weeks 
did not alter these levels [45]. In addition, expression of the androgen metabolizing enzyme, 5α-
reductase, was downregulated in the prostate and MatLyLu Dunning prostate tumor when rats 
were fed lycopene for four or eight weeks, respectively [46, 79]. In a rat model of testicular 
toxicity lycopene supplementation had no effect on androgen status [87]. Overall the available 
evidence suggests that short-term lycopene feeding may decrease androgen concentrations or 
signaling. A few studies have also investigated the effects of lycopene consumption on serum 
estrogen concentrations. All three in vivo human studies identified suggest that lycopene 
decreases estrogenic activity [88-90]. The evidence is mildly suggestive that lycopene may lower 
estrogen concentrations and/or activity. 
Another possible mechanism of action is that lycopene may induce detoxification 
enzymes. Our search yielded three publications that suggest lycopene induces rat hepatic phase II 
enzymes [91-93]. However, Breinholt, et al [92] failed to find that higher doses of lycopene 
induced phase II enzymes. Further, one human study and one rat study reported no effect of 
lycopene on detoxifying enzymes [94, 95]. The mixed results of these trials most likely relate to 
the doses/dietary levels of lycopene making it difficult to discern the effect of lycopene on phase 
II enzyme levels. 
A number of epidemiological studies suggest that lycopene decreases the inflammation 
marker, C-reactive protein (CRP). In healthy subjects, one human study reported that lycopene 
decreases CRP [96], while two studies reported no effect [97, 98]. There is little in vivo data on 
this topic, therefore we conclude that there is insufficient evidence to support that lycopene 
decreases CRP. 
It has also been suggested that lycopene may prevent atherosclerosis by decreasing the 
cell surface adhesion molecules expression and intima-media thickness. Three human studies 
[99-101] suggest that lycopene decreases cell surface adhesion and intima-media thickness, 
while three human [97, 98, 102] and one rat [103] study reported no relationship. Taken together, 
there is a lack of evidence to suggest that lycopene limits atherosclerosis by decreasing cell 
surface adhesion molecule expression or intima-media thickness. 
Lastly, it has been suggested that lycopene may act as a hypocholesterolemic agent. 
There are two extensive reviews on carotenoids and cardiovascular disease risk factors [104, 
105]. Only one human trial reported decreased total serum cholesterol with lycopene [96] while 
one study reported no effect on serum total, LDL, or HDL cholesterol [106]. In conclusion, there 
is little in vivo evidence to suggest that lycopene decreases cardiovascular disease risk by 
improving serum cholesterol profiles. 
Overall, the mechanisms with the greatest in vivo support include decreasing androgen 
and/or estrogen status or activity, and induction of apoptosis. However, only a limited number of 
studies have addressed the biochemical effects of lycopene. Many mechanistic studies lack in 
vivo experiments to support their findings, therefore more work is needed to clarify the 
mechanisms of action of lycopene. 
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Conclusions 
 
The focus of this paper was to review whether the health attributes of lycopene can be 
ascribed to its in vivo antioxidant function. A pubmed search was carried out with the search 
terms “lycopene AND antioxidant” and human intervention and animal studies were reviewed 
and evaluated. Evidence for lycopene’s in vivo mechanisms of action was also presented We 
conclude that there is limited experimental support for the “antioxidant hypothesis” as a major 
mechanism of lycopene’s in vivo action. As an alternative hypothesis, we suggest that the 
metabolic products of lycopene, the lycopenoids [4], may be more bioactive than the parent 
molecule and that lycopenoids may be more central to the health outcomes seen in vivo than the 
antioxidant properties of lycopene. Lycopenoids would not be expected to have direct 
antioxidant activity because of an insufficient number of conjugated double bonds. Instead, their 
impact on health would be more likely to through altering gene expression. 
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Table 1. Double-blind, placebo-controlled trials human studies examining the antioxidant potential of lycopene. 
Subjects [Ref] Source Amount 
(mg/day) 
Groups Admin Duration Outcome(s) 
Healthy Men & 
Women, ≥40 yrs [54] 
DSM 
Redivivo 
6.5, 15, 
30 
Pl ( n = 18) 
6.5 (n = 21) 
15 ( n = 17) 
30 ( n = 21) 
Capsule taken 
with low-fat 
milk 
2 wk Wo 
8 wk Sup 
30 mg ↓ lymphocyte DNA Damage 
(Comet), urinary 8-OHdG conc. vs. BL. 
NE - LDL oxidation rate, lipid 
peroxidation (MDA & HNE), and F2-
isprostane. 
Diabetics, 35-70 yrs 
[55] Unknown 10 
Pl ( n = 19) 
Lyc  ( n = 16) 
 
Unknown 2 wk Wo 8 wk Sup 
Lyc ↓ MDA vs. baseline & placebo. 
NE - TAC, oxidized LDL antibodies. 
 
Healthy Nonsmoking, 
postmenopausal 
women, 50-70 yrs 
[56] 
BASF 12 Pl ( n= 6) Lyc ( n = 8) 
Take with 1st 
meal that 
contained > 
10g fat 
2 wk Wo 
56 d Sup 
Lyc ↓ lymphocyte DNA damage 
(Comet). 
NE - hydrogen peroxide-induced DNA 
damage. 
Abbreviations: Admin, administration; BL, baseline; d, day; conc, concentration; HNE, 4-hydroxynonenal; LDL, low-density 
lipoprotein; Lyc, lycopene; MDA, malondialdehyde; NE, no effect; OHdG, 8-hydroxy-2'-deoxyguanosine; Pl, placebo; Ref, reference; 
Sup, supplementation; TAC, total antioxidant capacity; vs., versus; wk, week; Wo, washout; yrs, years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
 
Table 2. Human Studies examining the antioxidant potential of lycopene extracts1. 
Subjects Source Amount 
(mg/day) 
Groups Admin Duration Outcome(s) 
Healthy men (n = 18) 
and women (n = 9), 
21-24 yrs. [98] 
Lyc-O-Mato®
80 mg Lyc 
extract 
supplement, ~75 
mg/d Lyc 
Intervention 
Only 
4 capsules 
in morning 
& evening 
1 wk Wo 
1 wk Sup 
NE - serum MDA levels vs. 
baseline. 
Grade 1 
Hypertensives  
(n = 31), 30-70 yrs. 
[107] 
Lyc-O-Mato® 15 mg/d Intervention Only 
Take with 
main meal 
of day 
4 wk Pl 
8 wk Sup 
4 wk Pl 
↓ plasma TBARS vs. 
baseline. 
NE - plasma GSH thiols or 
GPx activity. 
Postmenopausal 
women (n = 20),  
< 60 yrs. [108] 
LycoRed 2 capsules (4 mg Lyc total 
Intervention 
Only Oral 6 mo 
↑ serum GSH conc vs. 
baseline. 
NE -serum MDA. 
Double-blind placebo 
crossover, male 
nonsmokers (n = 28), 
18-60 yrs. [109] 
LycoRed 15 mg/d Lyc Lyc-Pl Pl-Lyc Oral 4 wks 
NE - lymphocyte DNA 
damage (Comet). 
Double-blind, 
placebo-controlled, 
healthy nonsmokers 
& smokers, ave. age 
34.3 yrs. [110] 
Lyc-O-Mato® 3 capsules (~15 mg/d Lyc 
Pl nonsmokers 
(n = 15), 
smokers (n = 13) 
Sup nonsmokers 
(n = 15), 
smokers (n = 12) 
Given after 
dinner 
2 wk Wo 
2 wk Sup 
↑ lymphocytes with class 1 
or 2, or no DNA damage 
vs. Pl in nonsmokers. 
NE - lymphocyte DNA 
damage (Comet) overall. 
Randomized, cross-
over, 
ave. age 31.3 yrs. 
[111] 
Lyc-O-Mato® 5, 10, 20 mg/d Males (n = 6) Females ( n = 6) Oral 
2 wk Wo 
2 wk Sup 
↓ serum MDA, ↑ serum 
thiols. 
Randomized, 2-
armed, men with PCa 
prior to 
prostatectomy, 
<75 yrs. [33] 
Lyc-O-Mato® 2 capsules (15 mg Lyc)/d 
Cases (n =15) 
Controls (n = 11) Oral 3 wk 
NE - lymphocyte 5-
OhmdU. 
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Single-blind, placebo-
controlled, 
male nonsmokers,  
25-45 yrs. [112] 
Tomato 
Extract 
(Makhetsim 
Chem Works) 
1 capsule (15 mg 
Lyc)/d 
Pl ( n= 46) 
Sup ( n = 52) Oral 12 wk 
NE - LDL susceptibility to 
oxidation, FA ratio, GPx, 
SOD, GSH, GSSG, SH. 
Double-blind, 
placebo-controlled, 
healthy, 63-83 yrs. 
[113] 
Lyc-O-Pen™ 1 capsule (13.3 mg Lyc)/d 
Pl ( n = 16) 
Sup ( n = 16) Oral 12 wk NE - LDL oxidation. 
Abbreviations: 5-OhmdU, 5-hydroxymethyl-deoxyuridine; Admin, administration; Ave., average; d, day; FA, fatty acid; GPx, 
glutathione peroxidase; GSH, glutathione; GSSG, glutathione disulfide; LDL, low-density lipoprotein; Lyc, lycopene; MDA, 
malondialdehyde; NE, no effect; PCa, prostate cancer; Pl, placebo; SH, thiol; Sup, supplementation; TBARS, thiobarbituric acid 
reactive substances; vs., versus; wk, week; Wo, washout; yrs, years. 
1 Lyc-O-Mato® & Lyc-O-Pen™ are produced by LycoRed Ltd. (Beer Sheva, Israel). 
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Table 3. Modulation of chronic diseases biomarkers by lycopene or lycopene containing 
products1.  
Potential Mechanisms of Action References 
Decrease growth & inflammation 
↑ Apoptosis 
↓ Cell cycle progression 
↓ IGF-1 & ↑ IGFBP-3 
 
[31, 32, 45, 48, 68, 69, 72, 73] 
[48, 74] 
[32, 40, 46, 71, 77-80, 82] 
Increase gap junction communication [32, 83] 
Inhibit androgen / estrogen signaling [45, 46, 79, 86-90] 
Induce detoxification enzymes [91-95] 
Decrease cell surface adhesion & intima-media 
thickness [97-103] 
Decrease serum cholesterol [96, 106] 
Decrease C-reactive protein [96-98] 
1 Selected references that suggest lycopene mechanisms of action. 
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Supplemental Table 1. Animal Studies examining the antioxidant potential of lycopene. 
Model Source Amount 
(mg/kg) 
Admin Groups Duration Outcomes 
New Zealand 
White Rabbits 
[13] 
Huavei 
Pharmaceuticals 
Limited Co (90 
% Pure) 
4, 12 Diet High-Fat diet + 
Low Lyc (4) or 
High Lyc (12) 
8 wk Both Lyc diets ↑ serum TAC, ↓ serum 
MDA, & LDL oxidation vs. high-fat 
diet alone. 
Female Sprague 
Dawley Rats 
[14] 
Unknown 50 Diet Lyc after DMBA 120 d ↓ Serum & breast MDA vs. DMBA 
alone. 
↑ Breast SOD, CAT, & GPx vs. 
DMBA alone. 
Male Sprague 
Dawley Rats 
[15] 
DSM Redivivo 10 BW Gavage Lyc alone 
Lyc + Cyc A 
21 d ↓ renal TBARs, ↑ GPx vs. Cyc A 
alone. 
NE - renal GSH, CAT vs. Cyc A 
alone. 
NE - Lyc alone vs. control. 
Male Sprague 
Dawley Rats 
[16] 
BASF 50 Diet Lyc alone 6 wk NE - cardiac TBARs, hepatic GSH, 
erythrocyte SOD. 
Male Wistar-
Albino Rats [17] 
Unknown 10 BW Gavage Lyc alone 
Lyc + cadmium 
20 d ↓ serum & renal MDA vs. cadmium 
alone. 
NE - renal SOD, CAT, GPx vs 
cadmium alone. 
NE - Lyc alone vs. control. 
Male Sprague 
Dawley Rats 
[18] 
DSM Redivivo 10 BW Gavage Lyc + Saline 
Lyc + Cyc A 
21 d ↓ testis MDA, GPx, CAT vs. Cyc A 
alone. 
NE - Lyc alone vs. control. 
Male Sprague 
Dawley Rats 
[19] 
DSM Redivivo 4 BW Gavage 10 days before or 
5 d after cisplatin 
treatment 
 NE of Lyc treatment on testes MDA, 
GPx vs. cisplatin alone. 
Male Sprague 
Dawley Rats 
[20] 
DSM Redivivo 4 BW Gavage 10 days before 
(Pre) or 2 d 
before & 3 d 
 Post ↓ cardiac MDA, GSH, & CAT 
vs. adriamycin alone. 
Pre & Post ↓ renal MDA levels. 
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after (Post) 
adriamycin 
NE - of Pre or Post on renal GSH or 
CAT. 
Male Sprague 
Dawley Rats 
[21] 
DSM Redivivo 4 BW Gavage 10 d before or 5 
d after cisplatin 
treatment 
 ↓ renal MDA, GPx ,↑ renal GSH & 
CAT vs. cisplatin alone. 
 
Japanese Quail 
[22] 
DSM 100 or 200 Diet 100 mg/kg 
(Low) 
200 mg/kg 
(High) 
285 d ↓ serum & hepatic MDA vs. control. 
High ↓ serum & hepatic MDA vs. 
Low. 
F344 Male Rats 
[23] 
BASF 1000 Diet Lyc + PhiP 
Lyc + IQ 
15 d ↑ DNA & Protein adducts in liver 
(PhiP) & protein adducts in albumin 
(IQ) vs. control. 
NE - DNA adducts in colon, prostate, 
& liver (IQ) or protein adducts in 
albumin (PhiP) & liver (IQ), hepatic 
GST vs. control. 
Abbreviations: Admin, administration; BW, body weight; CAT, catalase; Cyc A, cyclosporine A; d, days; DMBA, 7,12-
dimetnylbenz[a]anthracene; GPx, glutathione peroxidase; GSH, glutathione; GST, glutathione-s-transferase; IQ, 2-amino-3-
methylimidazo[4,5-f]quinoline; LDL, low-density lipoprotein; Lyc, lycopene; MDA, malondialdehyde; NE, no effect; PhIP, 2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine; SOD, superoxide dismutase; TAC, total antioxidant capacity; TBARS, thiobarbituric acid 
reactive substances; vs., versus; wk, week; 
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Supplemental Table 2. Animal Studies examining the antioxidant potential of lycopene extracts. 
Model Source Amount 
(mg/kg) 
Admin Groups Duration Outcomes 
Male Wistar 
Rats [24] 
Lyc-O-Mato 30, 100, 
300 
Diet 2 wk before Den 
 
10 wk study 
Den given 
at wk 2 
Only 300 ↓ hepatic DNA damage 
(comet) vs. Den alone. 
 
Male Wistar 
Rats [25] 
Lyc-O-Mato 5 BW Gavage Lyc 
Lyc + Dox 
7 wk ↓ cardiomyocyte DNA damage 
(comet) vs. Dox alone. 
Male Wistar 
rats [26] 
LycoRed 1 BW Intragastric Lyc + 
Control ischemia-
reperfusion (CIR) 
31 d ↑ cardiac GSH, GPx , ↓ cardiac MDA 
vs. CIR. 
NE - cardiac SOD & CAT. 
Male Wistar 
rats [27] 
LycoRed 10 BW i.p. Lyc 
Lyc + Fe-NTA 
5 d ↓ hepatic MDA & 8-oxoGuo vs. Fe-
NTA alone. 
Male Wistar 
rats [28] 
LycoRed 2,4,6 
BW 
Acute 
0.5, 1, 
1.5 BW 
Sub 
acute 
Gavage Acute - 24 hr before 
cisplatin 
Subacute - 72, 48, 
24, 1 hr before 
cisplatin 
Unknown All treatments ↓ chromosomal damage 
vs. cisplatin alone. 
Male 
Sprague-
Dawley rats 
[29] 
LycoRed 2.6 
(Low) 
7.8 
(High) 
Diet Sedentary + Low 
Lyc 
Sedentary + High 
Lyc 
Exhaustive Exercise 
(EE) + Low Lyc 
EE + High Lyc 
30 d ↓ plasma  & muscle MDA levels in 
EE. 
NE - either dose in EE on erythrocyte 
& muscle GSH. 
NE - either dose in sedentary mice on 
plasma & muscle MDA, erythrocyte 
& muscle GSH. 
Male Wistar 
rats [30] 
LycoRed 200 Diet Ferrum 
Lyc + Ferrum 
10 d ↓ mucosa MDA, ↑ erythrocyte SOD 
vs. ferrum alone. 
Male Wistar 
rats [31] 
Lyc-O-Mato 1.25 Intragastric Lyc 
Lyc + MNNG 
 
5 d ↓ bone marrow micronucleated 
polychromatic erythrocytes & 
chromosomal aberrations vs. MNNG 
alone. 
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NE - Lyc alone vs.  control. 
Male Fisher 
344 Rats 
[32] 
LycoRed 50 Diet Lyc 10 wk ↑ lymphocyte pyrimidine & puridine 
oxidation. 
NE - lymphocyte DNA damage 
(Comet), hepatic GST, erythrocyte 
GPx, SOD, & CAT. 
Male Wistar 
Rats [33] 
Isolated 
from 
Blakeslea 
Trispora 
Fungus > 
80% pure 
10 BW 
50 BW 
Intragastric 10 mg/kg (Low) 
50 mg/kg (High) 
14 d High ↑ plasma TAC & ascorbate-
dependent lipid peroxidation vs. 
control. 
Both ↓ hepatic MDA & GST activity 
vs. control. 
NE - GPX, GR, CAT, NADPH-
dependent lipid peroxidation. 
Male Wistar 
Rats [34] 
Lyc-O-Pen 70 BW 
Every 
other 
day 
Gavage Lyc + Den 8 wk ↓ DNA damage (Comet) vs. Den 
alone. 
Male Syrian 
Hamsters 
[35] 
Lyc-O-Mato 2.5 BW 
3Xs/wk 
Intragastric Lyc 
Lyc + DMBA 
14 wk Lyc & Lyc + DMBA ↓ hepatic 
TBARS, ↑ GSH, GPx, GST, GR vs. 
control & DMBA alone, respectively. 
Male Wistar 
Rats [36] 
Lyc-O-Mato 2.5 BW 
3Xs/wk 
Intragastric Lyc 
Lyc + MNNG 
3 wk NE of either group on plasma & 
erythrocyte TBARS, GSH, GPx, GST, 
& GR. 
Male Syrian 
Hamster 
[37] 
Lyc-O-Mato 2.5 BW 
3Xs/wk 
Orally Lyc 
Lyc + DMBA 
14 wk Lyc & Lyc + DMBA ↓ buccal pouch 
mucosa TBARS, ↑ GSH, GPx, GST, 
GR vs. control & DMBA alone, 
respectively. 
LacZ Mice 
[38] 
Cognis 
Lycopene/to
mato 
oleoresin 
0.5 & 1 
mmol/k
g 
Diet 0.5 mmol/kg (Low) 
1 mmol/kg (High) 
8 wk 
(benzopyren
e) or 9 mo 
High Lyc ↑lung and colon mutations 
in benzopyrene animals. 
NE spontaneous mutations by high or 
low Lyc. 
Male Wistar 
Rats [39] 
LycoRed 10 BW i.p. Lyc 
Lyc + Fe-NTA 
5 d ↓ hepatic MDA & 8-oxoGuo vs. FE-
NTA alone. 
22 
 
NE - Lyc alone on hepatic MDA & 8-
oxoGuo vs. control. 
Female 
Wistar Rats 
[40] 
LycoRed 1 BW 
5 BW 
50 BW 
100 BW 
Gavage 1 mg/kg BW 
5 mg/kg BW 
50 mg/kg BW 
100 mg/kg BW 
2 wk 5, 50 ↑ erythrocyte SOD, 5 ↑ GR & 
GPx, 100 ↑ GST vs. control. 
NE - protein oxidation (2-amino 
adipic seimaldehyde), plasma MDA, 
before or after PhiP administration 
Broiler 
Chicks [41] 
Tomato 
hexane 
extract 
25 BW Diet Lyc 
Lyc + T-2 toxin 
7,14, 21 d ↓ hepatic MDA, GPx, GST, ↑GSH vs. 
T-2 toxin alone. 
Lyc alone ↑ hepatic GST. 
NE - Lyc alone on hepatic MDA, 
GSH, GPx vs. control. 
Abbreviation List: 8-oxoGuo, 8-oxo guanine; Admin, administration; BW, body weight; CAT, catalase; CIR, control. Ischemia-
reprefusion; d, days; Den, diethylnitrosamine; Dox, doxorubicin; EE, exhaustive exercise; Fe-NTA, ferric nitrilotriacetate; GPx, 
glutathione peroxidase; GR, glutathione reductase; GSH, glutathione; GST, glutathione-s-transferase; hr, hours; i.p., intraperitoneal 
injection; Lyc, lycopene; MDA, malondialdehyde; MNNG, N-methyl-N’-nitro-N-nitrosoguanidine; SOD, superoxide dismutase; 
TAC, total antioxidant capacity; vs., versus; wk, week. 
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